Literature DB >> 15325436

In vitro activity of voriconazole against Candida species isolated in Taiwan.

Yun-Liang Yang1, Hsiao-Hsu Cheng, Hsiu-Jung Lo.   

Abstract

The activity of voriconazole was determined against 285 Candida species consisting of 53 resistant isolates, 43 susceptible-dose dependent and 189 isolates susceptible to fluconazole. The MIC(50) and MIC(90) to fluconazole were 8 and 64 mg/l, respectively. The range of minimum inhibitory concentrations (MICs) to voriconazole was from 0.0325 to 2 mg/l and the MIC(50) and MIC(90) were 0.125 and 0.5 mg/l, respectively. Only 3 of 285 tested isolates had MICs to voriconazole equal to 2 mg/l. A total of 38 isolates, consisted of 3 Candida albicans, 5 Candida krusei, 7 Candida tropicalis and 21 Candida glabrata, had >/= 0.5 mg/l to voriconazole. There was correlation between the susceptibility to fluconazole and voriconazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15325436     DOI: 10.1016/j.ijantimicag.2004.01.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Characterization of Candida species from different populations in Taiwan.

Authors:  Yun-Liang Yang; Li-Yun Hsieh; An-Huei Wang; Hsiu-Jung Lo
Journal:  Mycopathologia       Date:  2011-03-03       Impact factor: 2.574

2.  Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole.

Authors:  Yun-Liang Yang; Chih-Chao Lin; Te-Pin Chang; Tsai-Ling Lauderdale; Hui-Ting Chen; Ching-Fu Lee; Chih-Wen Hsieh; Pei-Chen Chen; Hsiu-Jung Lo
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

3.  The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.

Authors:  Yun-Liang Yang; Shu-Ying Li; Hsiao-Hsu Cheng; Hsiu-Jung Lo
Journal:  BMC Infect Dis       Date:  2005-11-03       Impact factor: 3.090

4.  Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species.

Authors:  Ming-Fang Cheng; Yun-Liang Yang; Tzy-Jyun Yao; Chin-Yu Lin; Jih-Shin Liu; Ran-Bin Tang; Kwok-Woon Yu; Yu-Hua Fan; Kai-Sheng Hsieh; Monto Ho; Hsiu-Jung Lo
Journal:  BMC Infect Dis       Date:  2005-04-07       Impact factor: 3.090

5.  Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis.

Authors:  Zhidan Zhang; Ran Zhu; Zhenggang Luan; Xiaochun Ma
Journal:  BMJ Open       Date:  2020-07-12       Impact factor: 2.692

6.  Host factors do not influence the colonization or infection by fluconazole resistant Candida species in hospitalized patients.

Authors:  Yun-Liang Yang; Ming-Fang Cheng; Ya-Wen Chang; Tzuu-Guang Young; Hsin Chi; Sai Cheong Lee; Bruno Man-Hon Cheung; Fan-Chen Tseng; Tun-Chieh Chen; Yu-Huai Ho; Zhi-Yuan Shi; Chung-Huang Hubert Chan; Ju-Yu Lin; Hsiu-Jung Lo
Journal:  J Negat Results Biomed       Date:  2008-12-16

7.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.